Testing for mismatch repair (MMR) and microsatellite instability (MSI) among patients with colorectal cancer (CRC) increased from 22.7% in 2012 to 71.5% in 2021, but variations in access remain, with ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--Recognizing a need for evidence-based recommendations to guide molecular testing in the management of patients with cancer, the College of American Pathologists (CAP ...

The most recent guidelines recommend that all patients with colorectal cancer (CRC) be tested for deficient DNA mismatch repair (MMR), but until recently, this testing was recommended specifically for ...

Universal mismatch repair (MMR) deficiency testing is widely recommended in patients with colorectal cancer (CRC) and others with a family history of MMR deficiency to identify Lynch syndrome, a ...

Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation ...

Please provide your email address to receive an email when new articles are posted on . Although testing for microsatellite instability and mismatch repair deficiency has increased for advanced ...

Roche announced US Food and Drug Administration (FDA) approval of the Ventana MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--A new College of American Pathologists (CAP) evidence-based guideline is among the first to address testing based less on the cancer type or tumor origin and more on ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) ...